Newsroom

Team Rxtrospect Team Rxtrospect

FDA Grant Accelerated Approval for Genentech’s Bispecific Antibody, Columvi in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

FDA Grant Accelerated Approval for Genentech’s Bispecific Antibody, Columvi in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • Accelerated approval based Phase I/II NP30179 study of Columvi given as a fixed course for 8.5 months in 132 patients with r/r DLBCL, including about 30% who had received prior CAR T-cell therapy; 83% were refractory to their most recent therapy

  • Results showed 56% of patients achieving an overall response, 43% achieving a complete response

  • Over two-thirds of those who responded continued to respond for at least nine months (68.5%)

Read More
Team Rxtrospect Team Rxtrospect

FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

  • FDA follows ODAC advice, approving the sNDA for the restricted indication of BRCA-mutated mCRPC

  • Exploratory subgroup analysis in 85 patients with BRCAm (11% of ITT population) demonstrated a median rPFS that was not reached in the olaparib with abiraterone arm compared to 8 months (95% CI: 6, 15) for those receiving placebo with abiraterone (HR 0.24)

  • OS HR in these patients was 0.30 (95% CI: 0.15, 0.59)

Read More
Team Rxtrospect Team Rxtrospect

FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

FDA Approves AYVAKIT (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

  • Efficacy was based on the absolute mean change from baseline to Week 24 in the Indolent Systemic Mastocytosis-Symptom Assessment Form (ISM-SAF) total symptom score (TSS)

  • AYVAKIT demonstrated significant improvements versus PBO in the primary and all key secondary endpoints, including overall symptoms and measures of mast cell burden

  • AYVAKIT was well-tolerated with a favorable safety profile compared to placebo, and most adverse reactions were mild to moderate in severity

Read More
Team Rxtrospect Team Rxtrospect

FDA Approve EPKINLY™ (epcoritamab-bysp) as the First Bispecific Antibody to Treat Adults with r/r DLBCL

FDA Approve EPKINLY™ (epcoritamab-bysp) as the First Bispecific Antibody to Treat Adults with r/r DLBCL

  • EPKINLY monotherapy demonstrated responses in DLBCL patients who have received at least two prior treatments

  • Overall response (complete or partial response) was seen in 61% (90/148) of patients and 38% (56/148) achieved complete remission

  • Median DOR was 15.6 months (95 percent CI: 9.7-Not reached)

Read More
Team Rxtrospect Team Rxtrospect

Servier receives EU approval of Tibsovo® in IDH1-mutated AML and IDH1-mutated Cholangiocarcinoma

Servier receives EU approval of Tibsovo® in IDH1-mutated AML and IDH1-mutated Cholangiocarcinoma

  • In AML, a statistically significant improvement in EFS HR 0.33; & OS HR 0.44 was seen in patients treated with Tibsovo® in combination with AZA vs. AZA + PBO

  • In cholangiocarcinoma, a statistically significant improvement in PFS HR 0.37 was observed; mPFS for Tibsovo® and placebo was 2.7 and 1.4 months, respectively

Read More
Team Rxtrospect Team Rxtrospect

European Commission Approves BMS CAR T Breyanzi r/r Large B-cell Lymphoma After One Prior Therapy

European Commission Approves BMS CAR T Breyanzi r/r Large B-cell Lymphoma After One Prior Therapy

  • Breyanzi more than quadrupled median EFS compared to standard therapy (10.1 months vs. 2.3 months [HR: 0.349; 95% CI (0.229-0.530) p<0.0001]) at an interim analysis with a median follow-up of 6.2 months

  • Results of the primary analysis, with a median follow-up of 17.5 months were consistent with the interim analysis, with median EFS not reached for Breyanzi (95% CI: 9.5-NR) vs. 2.4 months for standard therapy (95% CI: 2.2-4.9)

Read More
Team Rxtrospect Team Rxtrospect

FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma

FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma

  • ORR in 121 patients was 68% (95% CI: 59, 76), including 12% with complete responses

  • mDOR for the dose escalation cohort + Cohort A was 22 months (range: 1+ to 46+) and for Cohort K was not reached (range: 1 to 24+)

  • This application was granted priority review and breakthrough designation

Read More
Team Rxtrospect Team Rxtrospect

FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation

FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation

  • This represents the first FDA approval of a systemic therapy for the first-line treatment of pediatric patients with LGG with a BRAF V600E mutation

  • ORR 46.6% in the D+T arm and 10.8% for those receiving C+V (p= <0.001). DOR was 23.7 months (95% CI: 14.5, not estimable) in the D+T arm and not estimable (95% CI: 6.6, not estimable) in the C+V arm

Read More